The enzyme arginase catalyses the divalent cation dependent hydrolysis of L-arginine to produce L-ornithine and urea. Two isoforms of arginases have been identified in mammalian (including human) cells. Moreover, some infectious pathogens (e.g. Leishmania) synthesize their own arginase. Work over the last decades has revealed that elevated arginase activity both decreases cellular availability in nitric oxide (NO) by competing with NO synthases (NOS) and increases concentration in L-ornithine, a precursor in the biosynthesis of polyamines which are important for cell differentiation and proliferation. From these data emerged the concept that selective arginase inhibitors might be a valuable strategy for treatment of various diseases associated with decreased NO and/or increased polyamines production. Consistent with this, recent research provides compelling evidence supporting the beneficial effects of arginase inhibitors in cardiovascular diseases (hypertension, ischemia reperfusion injury, atherosclerosis, diabetes mellitus), asthma, cancer, immunologically-mediated diseases or leishmaniasis. Despite active programs to identify potent arginase inhibitors, effective chemical compounds with reliable pharmacokinetics and toxicological properties are rare. The present review summarizes available data on the discovery of new arginase inhibitors from natural origin. Current knowledge on plant-derived compounds or extracts with arginase inhibitory properties as well as available data on structure-activity relationship (SAR) will be presented. Lastly, the present review will open up new prospects in order to improve the discovery of novel arginase inhibitors from natural sources.
INTRODUCTION
Arginases are trimeric metalloenzymes that catalyze hydrolysis of L-arginine to L-ornithine and urea (Fig. 1) . Their sequences are highly conserved across the living kingdom. Arginase in mammals has been identified as the final enzyme in the urea cycle. For this reason, urea cycle arginase, called liver arginase or arginase I (L-arginine urea amidino hydrolase, EC 3.5.3.1) is the best characterized form of the mammalian arginases. In the 1990s, the demonstration was made that a second arginase isoform existed in mammals, named arginase II. These two distinct arginase isoforms are encoded by distinct genes and have specific subcellular localization and tissue distribution. Arginase I (Arg I) is a cytosolic enzyme found at high levels in the liver, whereas arginase II (Arg II) is located within the mitochondrion and is expressed in various extra-hepatic tissues that lack complete urea cycle such as kidney, prostate, small intestine and lactating mammary gland [1] . Whereas Arg I plays a crucial role in urea cycle in the liver, Arg II is preferentially involved in nonhepatic tissues in Larginine homeostasis. In particular, this enzyme plays a key role in the biodisponibility of L-arginine to NO synthase by substrate competition, and via the formation of ornithine, regulates synthesis of many structural proteins including collagen, as well as synthesis of polyamines, the increase of which leads to cellular proliferation (Fig. 1) . Rat liver arginase was first cristallized as a trimeric enzyme with a binuclear manganese cluster as part of the catalytic site [2] . Human arginase I, a 322-residue protein cloned more than 20 years ago [3, 4] , is encoded by a gene localized on chromosome 6q23 [5] . Human arginase II was cloned in 1996 [6] [7] and the gene was mapped to chromosome 14q24.1-24.3 [8] . Human and rat type I arginases have 87% of their amino acid sequence in common, whereas human type I and II arginases share 55 % of amino acid residues. All these homotrimer enzymes present 100% homology in areas critical for catalytic activity. Each of the three subunits contains a binuclear manganese cluster in its independent active cleft site. In such catalytic site, each Mn 2+ ion is directly coordinated with one histidine and three aspartate residues [2, 9] . In native enzyme, the two Mn 2+ ions activate a hydroxide-bridged complex for nucleophilic attack at the guanidinium group of L-arginine. The reaction outcome is a tetrahedral intermediate, which then collapses to yield Lornithine and urea [10] .
In the past decades, various infectious pathogens including species of Leishmania, Schistosoma, Salmonella, Mycobacteria, or Helicobacter were found to express their own arginase. In Leishmania, arginase was located in the glycosome and seemed essential for the pathological rhythm of the parasite. It was involved in a complex balance that defined the fate of L-arginine [11] . More recently, a mitochondrial matrix arginase has been characterized in plants in which it catalyzes arginine to generate ornithine and urea. Arginase is the only enzyme in plants known to generate urea in vivo [12] .
Since the 1990s, renewal of interest in arginase has been stimulated by the discovery of the various biological functions of nitric oxide (NO) and the demonstration of a mutual interaction between NOS and arginase reaction paths (Fig. 1) . The fact that arginase might compete with NOS for their common substrate, L-arginine, and therefore regulate NO synthesis, opened up new avenues for the role of arginase in various diseases. There is now ample evidence that the upregulation of arginase pathway is involved in the pathophysiology of (1) cardiovascular diseases such as arterial hypertension, erectile dysfunction, atherosclerosis, diabetes, ageing, coronary diseases [13] , (2) respiratory diseases such as asthma [14] , (3) cancer [15] and (4) immunologically-mediated diseases [16] . Due to its generation of L-ornithine, arginase is also involved in important downstream metabolic pathways (Fig. 1) . L-ornithine can be further metabolized to polyamines which take part in a variety of fundamental cellular functions (cell proliferation, cell membrane transport). In pathogens such as Leishmania species, increased arginase activity is considered to play an important role in ornithine production [17] , the precursor of spermidine and trypanothione, which protects the parasite from oxidative stress and endogenous reactive oxygen species produced by the host's defense system [18, 19] . Moreover, the host uses a NO-dependent macrophage mechanism to kill Leishmania and Trypanosoma parasites. Actually, parasites could escape NO toxicity via depletion in L-arginine, mediated by an increase in macrophage arginase activity. In plants, although data are scarce, increased arginase activity might have a defensive role, acting as an anti-nutritional factor against phytophagous insects [20] or by reducing cellular proliferation in gall development [21] .
More recently, compelling evidence emerged that pharmacological arginase inhibitors hold great promise as new drugs for the treatment of cardiovascular diseases, asthma or infectious diseases. The beneficial effects of arginase inhibition have been largely demonstrated on animal disease models [for reviews see 13-16 and 22] . It is noteworthy that recent small-scale clinical studies brought a "proof of concept" for therapeutic application of arginase inhibition in human diseases. Local administration of arginase inhibitors through cutaneous microdialysis probe or via intra-arterial infusion improved vascular function in patients with hypertension [23] , type 2 diabete along with coronary artery disease [24] as well as heart failure [25] . Only a few organic compounds are available as arginase inhibitors. Among them, two boronic acid derivatives (S-(2-boronoethyl)-L-cysteine (BEC), 2-(S)-amino-6-boronohexanoic acid (ABH)) and one analogue of N-OH arginine (N(omega)-hydroxy-nor-L-arginine (nor-NOHA)) are the most potent. However, even though the characterization of their pharmacokinetic and toxical properties has not been extensively performed the boronic acid functionality of BEC and ABH might confer a potential toxicity as well as problematic pharmacokinetic properties upon such molecules [26] . Likewise, a recent study exploring pharmacokinetics of nor-NOHA highlighted its very short half-life [27] . For such reasons, given the high potential of arginase inhibition in the treatment of several human diseases, the discovery of new structures of arginase inhibitors is needed. Due to their high biological and chemical diversity, plants constitute a rich source of new active agents [28] in various areas including enzymatic inhibition [29] . The present review aims at summarizing the available data about plant-derived extracts or compounds with inhibitory properties on arginase activity. Data on SAR will also be provided. This review will end in suggesting attractive prospects in order to improve the discovery of novel arginase inhibitors from natural sources. Fig. 2 and Table 1) As indicated above, the discovery in the end of the 1990s that arginases compete with NO synthases for NO production led scientists to focus on the role of arginase in pathologies in which NO bioavailability plays a critical role, particularly in cardiovascular diseases associated with endothelial dysfunction. As a consequence, the research on natural arginase inhibitors from plants has been mainly related to investigating traditional medicinal plants with Rat kidney lysate (Arg II) 11.06μM
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In a study aiming at determining the mechanisms underlying the hypoglycemic action of Ficus glomerata Roxob [30] , Rahman et al. evaluated the effects of the plant on several enzymes including arginase. Their results showed that petroleum ether extract from the stem bark of F. glomerata inhibited arginase from rat liver homogenate. However, neither the half maximal inhibitory concentration (IC 50 ) of the extract nor its composition were determined in the above study.
Another study focussed on cocoa beans (Theobroma cacao), the major ingredient of cocoa and chocolate, a wellknown source of polyphenols that are able to improve endothelial function and to decrease blood pressure in humans and animals [31, 32] . In order to determine whether such cardiovascular properties were linked to arginase inhibition [33] , Schnorr et al. evaluated the effects of (-)-epicatechin, of a mixture of flavonol metabolites and of a flavonol-rich cocoa extract on expression and/or activity of arginase on different models in vitro and in vivo. In cultured endothelial cells (Human umbilical vein endothelial cells (HUVECs)), (-)-epicatechin (1) (1, 3 and 10 μM) as well as mixture of flavonol metabolites (0.4, 2.6 and 7.8 μM) significantly lowered activity in a dose-dependent manner (after a 48h-incubation) and Arg II mRNA expression (after a 24h-incubation). This effect was confirmed in male Sprague-Dawley rats fed with a 4% dietary flavanol-rich cocoa powder (w/w) containing (-)-epicatechin and its oligomers as major components. After a 28-days diet, kidney arginase activity significantly decreased (0.13 U/mL) as compared to untreated rats (0.18 U/mL, p<0.05). In healthy humans, the consumption of 200 mL of a flavonol-rich cocoa drink (containing 935 mg of total flavonols) induced a decrease in erythrocyte arginase activity after 24h (3 μmol/mg protein/h) as compared to control subjects (3.9 μmol/mg protein/h, p<0.05). Loranthus micranthus, also called African mistletoe, is a major traditional plant used to treat hypertension in Niger [34] . Consistent with its use in traditional medicine, the methanolic leaf extract of this plant exhibited antihypertensive activity in rat [35] . In a study aiming at determining the mechanisms of the antihypertensive activity of this extract, the treatment of mice with n-butanol or water fractions of methanolic leaf extract (250 mg/kg/day by gavage for 21 days) was reported to slightly decrease cardiac arginase activity by -12% and -8%, respectively [36] . The potential bioactive substances have not been isolated, but a phytochemistry screening of the active fraction identified polar constituents belonging to the class of terpenoids, steroids or tannins [36] .
Yucca schidigera, a desert plant, is considered having a variety of beneficial effects on health and is used in extracts and preparations included in human diet. Effects of the totum of this plant (TOT), as well as butanol (BE) and non-butanol (NBE) extractable fractions, have been evaluated on urea cycle enzymes activities including arginase in male Wistar rats [37] . Diet supplementation (200 mg/kg/day for 75 days) with TOT and BE significantly reduced liver arginase activity by 17 and 14%, respectively. Conversely NBE fraction was not active on arginase. Although the compounds responsible for arginase inhibition were not identified, the authors suggested that this activity could be attributed to saponins, sarsapogenin and smilagenin, contained in the BE fraction [38] . Unfortunately, this hypothesis is unlikely since the inhibitory effect of Y. schidigera extract on arginase observed in vivo was not confirmed on arginase from rat liver homogenate in vitro, despite the use of concentrations up to 1000 μg/g [37] .
For some years, the group of Ryoo and co-workers have concentrated their efforts upon finding plant-derived compounds able to inhibit arginase by using liver (Arg I) or kidney (Arg II) homogenates from C57BL/6 mice incubated with various extracts or pure compounds. Such procedure has enabled them to identify several medicinal plants of interest. Ethylacetate extract of the heartwood of Caesalpinia sappan, an Asiatic medicinal tree used for promoting blood circulation [39] exhibited a dose-dependent inhibitory effect on type II arginase (IC 50 = 36.82 μg/mL) [40] . This inhibition was further confirmed in both HUVECs and isolated mice aorta [40] . They have also investigated the effects of a water extract of Korean red ginseng known for its NO-dependent beneficial effects on cardiovascular system [41] . This extract inhibited both Arg I and Arg II in a dosedependent fashion [42] . In both studies the active compounds of plant extracts were not isolated. By contrast, in another study, the ethyl acetate fraction of the methanolic extract of the aerial part of Saurusus chinensis led to the isolation of two lignan-type compounds exhibiting arginase inhibitory properties, sauchinone (2) and hydroxysauchinone (3), with IC 50 values on Arg II of 89.6 and 61.4 μM, respectively [43] . Likewise, Scutellaria indica gave a series of flavonoids among them two flavanones, (4) and (5), were particularly active on Arg II (IC 50 (4) = 25.1 μM and IC 50 (5) = 11.6 μM) [44] . Moreover, piceatannol-3'-O-β-Dglucopyranoside (PG) (6), an isolated compound from rhubarb, the rhizome of Rheum undulatum L., exerted inhibitory activity on Arg I (IC 50 = 11.22 μM) and Arg II (IC 50 = 11.06 μM) [45] . The effect of PG on arginase activity was confirmed in HUVECs as well as in isolated mice aorta [44] . Similar data were obtained with obacunone (7), one of the oxygenated triterpenoids found in rutaceae family and having some arginase inhibitory effect [46] . Of interest, salvianolic acid B (Sal B) (8) isolated from the root of Salvia miltiorrhiza (Danshen), a Chinese herbal medicine commonly used for the prevention and treatment of cardiovascular diseases, induced a dual action on arginase. While Sal B increased arginase activity of cultured RW 264.7 macrophages, it inhibited arginase activity in liver, kidney and aorta [47] . The reasons for such a discrepancy between the effects of Sal B on macrophages and other tissues have not been elucidated yet. Fig. 3 and Table 2) Arginase activity has been detected in several genera of parasites from the Trypanosomatidae family [11] . Among them Leishmania species are the causative agents of various clinical diseases called leishmaniasis. Recent insights have demonstrated that arginase pathway is crucial for parasite 
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Chlorogenic acid (9) n. (-)-Epicatechin (1) n.d. (-)-Epicatechin-3-gallate (12) Gallic acid (13) 3.8 μM viability and infectivity. Actually arginase is the first step enzyme of the metabolic pathway of polyamines which are essential for cell proliferation and production of trypanothione, a compound involved in the detoxification of reactive oxygen species produced by host cell for its defense [48] . In the last years, these data have motivated the search for inhibitors of Leishmania arginase [49] . Maquiaveli and coworkers screened plant extracts using recombinant arginase from L. (L.) amazonensis as model. They showed that a methanolic leaf extract of Cecropia pachystachya, a Brazilian traditional plant, possessed interesting activity (90% of inhibition at 10 μg/mL). The bioguided fractionation of this extract led to the identification of active polyphenol-type molecules inducing inhibition above 50% at 20 μM: chlorogenic acid (9), (+)-catechin (10), (-)-epicatechin (1) and the most active compound, the glucoside flavonoid orientin (11) (IC 50 = 16 μM) [50] . Then, a series of 13 flavones and flavonols were tested for their ability to inhibit arginase and for structure relationship studies. Eight of these molecules showed a significant inhibitory activity with percentages of inhibition achieving 50% to 87% at 125 μM and IC 50 values ranging between 1.4 μM and 16 μM [51, 52] ( Table 2 ). These studies revealed that the lack of catechol group drastically decreased arginase inhibition [52] and docking analysis of the flavonoids suggested that the catechol group interacts with Asp 129 which is involved in metal bridge formation for the two Mn
2+
-cofactors in the site of arginase [51] . The hydroxyl group at position 3 contributed significantly to the inhibitory activity whereas the hydroxyl group at position 5 did not [52] (Fig. 4) . To investigate the potential of flavanol-type molecules to inhibit Leishmania arginase, epigallocatechin-3-gallate (EGCG, 12), (+)-catechin (10) and (-)-epicatechin (1) were evaluated together with gallic acid (13) . A range of low IC 50 values were obtained with all these compounds [53] (Table 2) .
In another study [54] , crude ethyl acetate extracts from the leaves and stems of Byrsonima coccolobifolia, a Brazilian Cerrado plant, were identified as potential Leishmania arginase inhibitors, with more than 60% inhibition of recombinant arginase from L. (L.) amazonensis at 31.25 μg/mL. The bioactivity-guided fractionation of these extracts led to a series of active compounds: (+)-syringaresinol (14) , trigonostemone (15) and several known flavonoids (Table 2, Fig. 3) . In order to establish SARs for inhibitory activity of arginase, the authors evaluated further natural and hemisynthetic flavonols and flavanols. According to previous data [52] , they concluded that an increase in the number of free hydroxyls on B ring of flavonols correlated with an increase in arginase inhibitory -cofactors in the site of arginase); (ii) the increase in the number of free hydroxyls on B ring correlated with an increase in arginase inhibitory effect; (iii) the hydroxyl group at position 3 contributed significantly to the inhibitory activity whereas the hydroxyl group at position 5 did not; (iv) the substitution of one or several hydroxyl groups with methoxyl or acetate groups led to a decrease in the effect. (B) Flavan-3-ols: (i) Flavan-3-ols are also good Leishamnia arginase inhibitors suggesting that the cetone on C ring is not required for activity; (ii) acetylation at different positions did not affect the enzyme inhibition activity (contrary to flavonols). Adapted from ref. [50] [51] [52] .
effect. Moreover, the replacement of one or several hydroxyl groups with methoxyl or acetate groups in flavonols led to a decrease in the effect. However, in flavan-3-ols, acetylation at different positions did not affect the enzyme inhibition activity (Fig. 4) . The authors did not provide hypothesis to explain this latter result.
CONCLUSION AND PERSPECTIVES
Although accumulated data on arginase suggest that the development of arginase inhibitors is of great therapeutic relevance in various human diseases, only a few effective chemical arginase inhibitors are available. Even though the pharmacokinetics and toxicological properties of these inhibitors have not been fully characterized, it seems unlikely that these molecules could be suitable for clinical application [26] . The studies presented in this review provide the seminal information that plants contain natural arginase inhibitors. The available data identified plant-derived polyphenols as important sources of mammalian and/or Leishmania arginase inhibitors. Further studies are warranted to explore the effect of other classes of plant metabolites such as terpenoids, steroids, tannins, saponines or alkaloids which are present in different extracts showing arginase inhibitory activity. A few studies on SAR of flavonoids against Leishmania arginase provided interesting elements but such investigations are needed for mammalian arginases. Surprisingly, hypothesis that plant-derived compounds or plant extracts might decrease arginase activity via a biophysical mechanism has never been explored. However, recent data [55, 56] revealed that naturally occurring substances such as aliphatic alcohols or phenolic compounds can act as chaotropic agents, i.e. compounds able to disrupt the hydrogen bonding network between water molecules. The biological consequence is the reduction of the stability of native state of macromolecules including enzymes by weakening their hydrophobic effect [55] . Therefore studies aiming at determining the mode of action of new plantderived arginase inhibitors should include the evaluation of their potential chaotropicity [57] .
With the aim of developing the research of new arginase inhibitors derived from natural sources, it appears that important methodological issues require consideration. First, it is necessary to systematically include a commercially available reference inhibitor of arginase (BEC, ABH or nor-NOHA) in experiments evaluating the effect of a new extract or compound. Indeed the methods used in terms of models (cultured cells, tissue homogenates, recombinant arginase...) and biochemical conditions for arginase assay (enzyme/ substrate concentrations, color reagent…) are currently too different from one study to another to allow valid comparisons. Second, it should be necessary at least to determine the IC 50 value of the extract or pure compound and to compare this value to that of reference inhibitor, and better, to determine the Ki (dissociation or inhibition constant) of each compound to overcome the differences in experimental conditions among studies. Third, for the studies aiming at identifying new arginase inhibitors targeting human arginases, the use of recombinant human arginases for in vitro screening tests would be desirable. Fourth, because no isoform-selective arginase inhibitor is currently available, it could be important to use both Arg I and Arg II in screening tests, in order to discover compounds able to discriminate both isoforms. Finally, the most potent arginase inhibitors from natural sources should be tested in relevant experimental animal models of diseases. In conclusion, the discovery of natural molecules inhibiting arginase activity is a very promising research area since on the one hand, it might provide novel structures that could be used for designing pharmaceutical compounds and on the another hand, it might allow a dietary approach to diseases associated with arginase pathway upregulation.
